At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,032 enrolled
Drug / intervention
AG200-15drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm, Open-label, Multicenter Phase 3 Study of the Contraceptive Efficacy, Safety and Tolerability of the AG200-15 Transdermal Contraceptive Delivery System (TCDS)
In Brief
A Phase 3 clinical trial evaluating AG200-15 for Healthy. Completed, enrolled 2,032 participants.
Detailed Summary
Study of the efficacy of a contraceptive patch in 2100 healthy women for up to one year.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartAug 2014
Primary CompletionNov 2016
TodayJul 2026
First PostedJun 9, 2014
Enrollment StartAug 1, 2014
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.1 years ago
Interventions
AG200-15drug
Transdermal contraceptive delivery system